Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients

AstraZeneca268 enrolled

Overview

The aim of this study is to evaluate the effectiveness of Rosuvastatin versus Ezetimibe/Simvastatin in dyslipidemic patients treated for at least 8 weeks.

Study Type

OBSERVATIONAL

Enrollment

268

Conditions

Dyslipidemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Dislipidemic population treated with rosuvastatin or ezetimibe/simvastatin for at least for 8 weeks * Who have completed at least 80% of the treatment * To have determinations at least of CT, TG C-LDL and CHDL before starting treatment and after 8 weeks of taking the medicine Exclusion Criteria: * Initiating different therapy lipid lowering to Rosuvastatin or Ezetimibe/Simvastatin

Locations (9)

Research Site

Guadalajara, Jalisco, Mexico

Research Site

Mexico City, Mexico City, Mexico

Research Site

Cuernavaca, Morelos, Mexico

Research Site

Monterrey, Nuevo León, Mexico

Outcomes

Primary Outcomes

The percentage of the patients that achieve the goal proposed for NCEP ATP III (2001 y 2004) will be assessed, to C-LDL in patients treated with Rosuvastatin or Ezetimibe/Simvastatin at least for 8 weeks.

Time frame: Data will be collected using CRFs after complete at least 15 patients over a 24 week period.

Secondary Outcomes

The percentage of LDL-C reduction according to baseline levels in patients treated wuth Rosuvastatin or Ezetimibe/Simvastatin for at least 8 weeks.

Time frame: Data will be collected using CRFs after complete at least 15 patients over a 24 week period.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.